Heidelberg Pharma Narrows 2026 Loss, Advances ADC Trials & NMPA Approval
Heidelberg Pharma cuts its 9‑month 2026 loss to €8.7 M, extends liquidity, and advances ADC oncology trials with new Chinese approval and a Huadong partnership.
2 minutes to read